Syqe Medical Receives First-Ever Health Canada Approval for Medical Cannabis Dosing Device

TORONTO– Syqe Medical, a pharma-tech company, announces today that Health Canada has approved the Syqe Inhaler, the first pharmaceutical grade medical cannabis delivery device system, they say, that provides predictable and consistent dosing through inhalation.

The Syqe Inhaler has a metered-dose delivery system allows the patient to benefit from very low doses of medical cannabis and is easy for both physicians and patients to understand and use.

“Syqe Medical is proud to bring this first-in-class device, which delivers a specific dose of cannabinoids with each inhalation, helping to relieve symptoms with few, if any, adverse reactions,” said Perry Davidson, founder and CEO of Syqe Medical.  “It is our hope that the Syqe^® Inhaler will help alleviate physician concerns about adverse reactions and psychoactivity when prescribing medical cannabis.”

According to a recent post marketing report patients using the Syqe Inhaler, at one year and beyond, reported no adverse reactions.ⁱ

Due to its dosing capability, the novel drug delivery technology helps eliminate uncertainty surrounding dosage administration and allows physicians to consider and recommend appropriate dosages of medical cannabis with more consistent results.

“This proprietary technology has great potential for medical cannabis use,” said Dr. Peter M. Blecher, Medical Director, CPM Centres for Pain Management. “Cannabis for medical use has been hampered by unreliable dosing methods, such as smoking, and physicians have been looking for an appropriate alternative. Finding the dose that provides a consistent result has been problematic for health care professionals. The Syqe Inhaler, with its precision and consistent micro-dosing capability can satisfy this unmet need. It may now be possible to provide patients with relief without unwanted effects.”

A placebo-controlled, double-blind, multi-dose study conducted by Syqe Medical and published in the European Journal of Pain confirmed that microgram-doses of THC (the main psychoactive component of cannabis) administered through the Syqe Inhaler can be effective in relieving pain, without psychoactive effects.ⁱⁱ

The study shows that an optimally effective dose is 500 micrograms of THC – A typical medical cannabis patient consumes one gram of 15 per cent THC cannabis per day, which contains 150,000 micrograms of THC, 100x the amount needed for pain relief. Accordingly, the study shows that when THC is delivered with greater precision to the patient, lower doses are needed, resulting in greater overall efficacy and fewer side effects, such as potentially debilitating psychoactivity.  Consequently, as the study demonstrates, the Syqe Inhaler metered dosing capabilities and pre-filled medical cannabis cartridges allows patients, for the first time, to benefit from predictable microgram-level doses of THC with unprecedented precision and low risk of unwanted side effects.

“Before being approved in Canada, the technology used in the Syqe Inhaler went through ten years of research and development, including testing in a variety of research trials,” said Michael Milloy, General Manager of Syqe Medical in Canada. “We are proud of the extensive research that went into bringing the inhaler to Canada and the rigorous clinical evidence that supports its use.”

The Syqe Inhaler will be made available through Syqe Medical Canada in partnership with a Canadian Licensed Producer for individuals with a valid medical authorization document.

(This information is primarily sourced from Syqe Medical.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).